News
Zepbound beats Wegovy for weight loss
Digest more
Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.
A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...
Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results